Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma (Q37423758)

20 August 2017

1 reference

title

Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma (English)

1 reference

systemic lupus erythematosus

20 August 2017

1 reference

1 reference

Chi Chiu Mok

1

1 reference

PubMed ID

19322186

20 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

Nature Reviews Nephrology

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

4

1 reference

20 August 2017

212-220

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2009.14

20 August 2017

0 references

cites work

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Causes and predictors of death in South Africans with systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Outcome of silent lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Prognostic determinants in lupus nephritis: a long-term clinicopathologic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Clinical and pathological features of membranous glomerulonephritis of systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

The classification of glomerulonephritis in systemic lupus erythematosus revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Treatment of membranous lupus nephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Factors affecting outcome and prognosis in membranous lupus nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Clinical presentation and outcome in a cohort of paediatric patients with membranous lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Long-term outcome of Chinese patients with membranous lupus nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

The very long-term prognosis and complications of lupus nephritis and its treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Membranous nephropathy: when and how to treat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Premature coronary-artery atherosclerosis in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Nonimmunosuppressive therapy of membranous nephropathy

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

31 March 2020

12 December 2020

Effect of pravastatin on proteinuria in patients with well-controlled hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Severe bone marrow failure associated with the use of alternating steroid with chlorambucil in lupus membranous nephropathy in Chinese

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Good response of membranous lupus nephritis to tacrolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Sequential therapies for proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Lupus nephritis: treatment with mycophenolate mofetil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Mycophenolate therapy of SLE membranous nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Mycophenolate mofetil in lupus glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Current treatment of lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.14

Cyclosporine treatment of lupus membranous nephropathy

31 March 2020

1 reference

12 December 2020

Lupus nephritis: clinical and pathological correlation

1 reference

12 December 2020

Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome

1 reference

12 December 2020

Renal biopsy in lupus patients with low levels of proteinuria.

1 reference

12 December 2020

Cyclosporine A in treatment of membranous lupus nephropathy

1 reference

12 December 2020

Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy

1 reference

12 December 2020

Lupus membranous nephropathy: long-term outcome

1 reference

12 December 2020

Lupus nephritis in children--a review of 167 patients

1 reference

12 December 2020

Membranous glomerulopathy in systemic lupus erythematosus.

1 reference

12 December 2020

Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group.

1 reference

12 December 2020

Membranous lupus nephropathy: a clinicopathologic study

1 reference

12 December 2020

A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.

1 reference

12 December 2020

Lupus membranous glomerulonephritis: different prognostic subgroups obscured by imprecise histologic classifications.

1 reference

12 December 2020

A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2009.14

1 reference

20 August 2017

1 reference

PubMed ID

19322186